Johnson & Johnson Reports TREMFYA Axial PsA Study Data
Spring House, Pennsylvania, September 25, 2026 Johnson & Johnson announced topline results from the Phase 4 STAR study evaluating...
psoriatic arthritis
Advertisement
Bristol Myers Squibb Reports Durable Sotyktu Results in PsA
PRINCETON, N.J. — September 17, 2026 Bristol Myers Squibb announced positive two-year results from the Phase 3 POETYK PsA-2...
Greywolf Therapeutics Advances GRWD0715 Into axSpA Trial
LONDON — September 8, 2026 Greywolf Therapeutics announced that it has dosed the first participants with axial spondyloarthritis (axSpA)...
Spyre Reports SPY072 Rheumatoid Arthritis Phase 2 Results
WALTHAM, Mass. — August 25, 2026 Spyre Therapeutics, Inc. announced topline results from the rheumatoid arthritis (RA) sub-study of...
MoonLake Reports Positive Phase 3 PsA Results for Sonelokimab
ZUG, Switzerland, August 10, 2026 MoonLake Immunotherapeutics announced positive topline results from its Phase 3 IZAR-1 trial evaluating investigational...
Advertisements
MoonLake Reports Strong Phase 3 Sonelokimab HS Results
ZUG, Switzerland, June 21, 2026 MoonLake Immunotherapeutics has announced compelling Week 52 results from its Phase 3 VELA clinical...
Samsung Bioepis and Organon Expand PYZCHIVA Rights in Canada
INCHEON, South Korea & KIRKLAND, Quebec, Canada, June 18, 2026 Samsung Bioepis and Organon have expanded their long-standing biosimilar...
Johnson & Johnson Wins FDA Label Expansion for TREMFYA
HORSHAM, Pennsylvania, May 28, 2026 Johnson & Johnson has secured a major regulatory milestone after the U.S. Food and...
Samsung Bioepis Launches First Japan Biosimilar
INCHEON, South Korea, May 20, 2026 Samsung Bioepis has announced the official launch of Ustekinumab BS 45 mg Syringe...
Bristol Myers Squibb Secures EU Approval for Sotyktu in Psoriatic Arthritis
PRINCETON, N.J., May 11, 2026 Bristol Myers Squibb announced that the European Commission has approved Sotyktu (deucravacitinib) for the...
Advertisement
